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Alzheimer's disease (AD) is a chronic neurodegenerative
disorder and the most common course of dementia,
affecting more than 20 million people worldwide. Today,
AD can be diagnosed only post mortem, detecting insolu-
ble beta-amyloid peptide (Abeta) aggregates and neurofi-
brillary tangles in the patient's brain tissue.
The development of a therapeutic approach or a potential
prevention strategy to AD is still severely hampered by the
lack of a reliable method to diagnose AD at stages as early
as possible. The method of choice would be able to corre-
late the result with the stage of the disease progression.
Further, it needs to be non-invasive and repeatedly appli-
cable to living patients.
In our group we will develop an ultra-sensitive assay for
early and non-invasive diagnosis of AD. This highly spe-
cific and sensitive assay uses fluorescence correlation spec-
troscopy (FCS) and is sensitive enough to detect even
single aggregates. The principle of the assay has already
been shown to be successful to detect prion-protein aggre-
gates in brain homogenate (1). Prion-protein aggregates
are the characteristic feature of prion diseases like bovine
spongiform encephalopathy (BSE).
Based on the experiences from the prion-protein aggregate
assay, a procedure will be developed to obtain prepara-
tions from tissues and bodily fluids (e.g. blood and liq-
uor) that contain Abeta aggregates (e.g. fibrils), which will
be captured on a surface and subsequently be tagged with
fluorescent-labelled specific antibodies or other probes.
Thereby, even single aggregates will be detected by scan-
ning the surface with an FCS-based method.
Further, the correlation of Abeta concentrations (aggre-
gated) in tissues and bodily fluids with clinical symptoms
of AD will be investigated.
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